DUBLIN–(BUSINESS WIRE)–The “Ocular Hypertension – Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. Ocular Hypertension – Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Ocular Hypertension (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological actio
Author: Business Wire
Physicians Protocol Joins the AcuFocus IC-8® Lens Clinical Study for Patients with Cataracts
GREENSBORO, N.C.–(BUSINESS WIRE)–Karl Stonecipher, MD at Physicians Protocol, is participating in the AcuFocus clinical study for the IC-8 intraocular lens designed for cataracts.
Global Handheld Retinal Scanners Market Outlook to 2026 – Anticipating a CAGR of 17.3% – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Handheld Retinal Scanners Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026” report has been added to ResearchAndMarkets.com’s offering. The global handheld retinal scanners market is expected to reach from US$ 790.3 Mn in 2017 to US$ 3,216.3 Mn by 2026 expanding at a CAGR of 17.3% from 2018 to 2026. The advantages associated with retinal scans are a low occurrenc
Samsung Awards Three Schools $100,000* for Using STEM to Tackle School Shootings, Pedestrian Fatalities and Healthcare Access
RIDGEFIELD PARK, N.J.–(BUSINESS WIRE)–Samsung Electronics America, Inc. announced today the three grand prize national winners in the ninth annual $2 million* Samsung Solve for Tomorrow Contest – a national competition that challenges public school s…
Alcon Announces Timothy Stonesifer as Chief Financial Officer
FORT WORTH, Texas–(BUSINESS WIRE)–Alcon Announces Timothy Stonesifer as Chief Financial Officer.
Ocular Therapeutix™ Announces Notification of FDA Acceptance of Supplemental New Drug Submission for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery
BEDFORD, Mass.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24OCUL&src=ctag" target="_blank"gt;$OCULlt;/agt; lt;a href="https://twitter.com/hashtag/OCUTX?src=hash" target=&…
Lantheus Enters Strategic Collaboration with Cerevast for Potential New Eye Care Application Using Microbubbles
NORTH BILLERICA, Mass.–(BUSINESS WIRE)–Lantheus Enters Strategic Collaboration with Cerevast for Potential New Eye Care Application Using Microbubbles
Aerie Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucom…
Contact Lenses & Solutions, 2019 – Global Market Analysis, Trends and Forecasts Through 2016-2024 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Contact Lenses and Solutions – Market Analysis, Trends, and Forecasts” report has been added to ResearchAndMarkets.com’s offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa, and Latin America. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. This report analyzes the worldwide markets in
Aura Biosciences Completes $40 Million Series D Financing
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that it closed a $40 million Series D financing. New investor Medicxi led the round, with current investors…
Fera Pharmaceuticals Announces FDA Approval of Avaclyr™ (acyclovir ophthalmic ointment)
NEW YORK–(BUSINESS WIRE)–The US Food and Drug Administration (FDA) has approved Fera’s New Drug Application (NDA) for Avaclyr™ (acyclovir ophthalmic ointment) 3% for the treatment of herpetic keratitis. Orphan drug exclusivity was also granted, provi…
Gloal Spectacle Lens Market Growth, Trends, and Forecast 2019-2024: Prescription Glass Segment is Expected to Exhibit Fastest Growth Rate – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Spectacle Lens Market – Growth, Trends, and Forecast (2019 – 2024)” report has been added to ResearchAndMarkets.com’s offering. The growth of the global spectacle lens market is due to the increasing geriatric population and rising prevalence of optical disorders. Globally, the percentage of the elderly population increased from 5.6% to 8.6% between 1961 and 2011. According to the US Census Bureau’s Statistics, among 7.3 billion people in the world, in 2015 an esti
NovaBay Pharmaceuticals Announces Investments of $5 Million to Support U.S. Avenova Commercialization Strategy
EMERYVILLE, Calif.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/Avenova?src=hash" target="_blank"gt;#Avenovalt;/agt;–NovaBay Pharmaceuticals Announces Investments of $5 Million to Support U.S. Avenova Co…
Aerie Pharmaceuticals Announces Appointment of Gianluca Corbinelli as Chief Commercial Officer – Europe
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucom…
NovaBay Pharmaceuticals Reports 2018 Fourth Quarter and Full Year Financial Results
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, reports financial results for the three and 12 mon…
Zenni Optical Celebrates 25 Million Glasses Sold and Over 15 Years of Disrupting Industry-Controlled Pricing
NOVATO, Calif.–(BUSINESS WIRE)–Zenni Optical, the online optical industry leader, celebrates the company’s sweet 16 birthday with more than 25 million pairs of glasses sold. Zenni continues to see strong growth year-over-year and in 2018 alone, the o…
Vision Care Market – Global Outlook and Forecasts 2019-2024 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Vision Care Market – Global Outlook and Forecast 2019-2024” report has been added to ResearchAndMarkets.com’s offering. The global vision care market is expected to reach around $74 billion, growing at a CAGR of more than 3% during the forecast period. The global vision care market is driven by the increasing number of vendors collaborating with healthcare providers to promote and encourage customers to use the latest eye care products. The exponential growth in No
Vivior’s Produkt für CE-Kennzeichnung gemeldet – Markteinführung in Europa in diesem Jahr
ZÜRICH–(BUSINESS WIRE)–Vivior kann das von ihr entwickelte Produkt mit dem CE-Zeichen der Klasse I versehen und plant noch in diesem Jahr die Markteinführung in der Schweiz und der Europäischen Union. Vivior hat bei Swissmedic ihr Produkt, den «Visua…
Le système Vivior est homologué marquage CE – Introduction sur le marché européen cette année
ZURICH–(BUSINESS WIRE)–Vivior a homologué son système en tant que dispositif médical de classe I et prévoit son introduction sur le marché en Suisse et dans l’Union européenne plus tard cette année. Vivior a déclaré à Swissmedic son produit, le Visual Behavior Monitor, et satisfait à toutes les exigences d’un dispositif médical de classe I selon la directive sur les dispositifs médicaux (MDD). Grâce à cette étape importante, Vivior est maintenant autorisée à vendre son système en Suisse et da
Riassunto: Il sistema di Vivior è notificato per il marchio CE – Quest'anno il lancio sul mercato europeo
ZURIGO–(BUSINESS WIRE)–Vivior ha notificato suo sistema come dispositivo medico di Classe I e sta pianificando l’introduzione sul mercato quest’anno in Svizzera e nell’Unione Europea. Vivior ha informato Swissmedic del proprio prodotto, il Visual Behavior Monitor, che soddisfa tutti i requisiti di un dispositivo medico di Classe I secondo la Direttiva dei dispositivi medici (Medical Device Directive, MDD). Avendo raggiunto questo importante traguardo, ora Vivior può vendere il proprio sistema